{
    "2018-01-02": [
        [
            {
                "time": "2018-01-02",
                "original_text": "The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S",
                "features": {
                    "keywords": [
                        "Johnson and Johnson",
                        "AbbVie",
                        "Roche",
                        "AstraZeneca",
                        "Novo-Nordisk"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (31 December 2017)",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "own shares",
                        "holding"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "In pharma space, we like Tecan and Novo Nordisk: Aberdeen...",
                "features": {
                    "keywords": [
                        "Tecan",
                        "Novo Nordisk",
                        "Aberdeen"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}